Beam Therapeutics Inc. (BEAM) Q3 2024 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Beam Therapeutics Inc..

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:04.497 Good morning and welcome to the BEAM Therapeutics conference call. 00:00:04.497 -- 00:00:08.201 At this time, all participants are in a listen-only mode. 00:00:08.201 -- 00:00:11.465 There will be a question and answer session at the end. 00:00:11.465 -- 00:00:16.011 Please be advised that this call is being recorded at BEAM's request. 00:00:16.011 -- 00:00:21.297 I would now like to turn the call over to Holly Manning, Vice President of Investor Relations 00:00:21.297 -- 00:00:23.858 and External Communications. 00:00:26.288 -- 00:00:30.253 Thank you, operators. Good morning, everyone, and welcome to BEAM's conference call to 00:00:30.253 -- 00:00:36.121 review third quarter 2024 business updates, including abstracts accepted for presentation 00:00:36.121 -- 00:00:39.345 at the American Society of Hematology Annual Meeting. 00:00:39.345 -- 00:00:43.551 You can access slides for today's call by going to the investor section of our website, 00:00:43.551 -- 00:00:45.394 beamtx.com. 00:00:45.394 -- 00:00:50.892 With me on the call today with prepared remarks are John Evans, our Chief Executive Officer, 00:00:50.892 -- 00:00:54.517 Dr. Giuseppe Pino Taramella, our president, and Dr. 00:00:54.517 -- 00:00:59.324 Amy Simon, our chief medical officer. Before we get started, I would like to remind everyone 00:00:59.324 -- 00:01:03.149 that some of the statements we make on this call will include forward-looking statements 00:01:03.149 -- 00:01:08.116 for purposes of the safe harbor provisions under the Private Securities Litigation Reform 00:01:08.116 -- 00:01:13.183 Act of 1995. Actual events and results could differ materially from those expressed 00:01:13.183 -- 00:01:18.050 or implied by any forward-looking statements as a result of va...